Menu Search
Equities

Carl Zeiss Meditec AG

AFXX:GER

Carl Zeiss Meditec AG

Actions
Health CareMedical Equipment and Services
  • Price (EUR)54.65
  • Today's Change-2.25 / -3.95%
  • Shares traded171.86k
  • 1 Year change-36.50%
  • Beta0.8120
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform2
Hold11
Sell4
Strong Sell0

Share price forecast in EUR

The 17 analysts offering 12 month price targets for Carl Zeiss Meditec AG have a median target of 66.00, with a high estimate of 104.00 and a low estimate of 54.00. The median estimate represents a 15.99% increase from the last price of 56.90.
High90.3%104.00
Med20.8%66.00
Low-1.2%54.00

Dividends in EUR

In 2023, Carl Zeiss Meditec AG reported a dividend of 1.10 EUR, equaling last years dividend. The 17 analysts covering the company expect dividends of 0.86 EUR for the upcoming fiscal year, a decrease of 21.73%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in EUR

On Aug 06, 2024, Carl Zeiss Meditec AG reported 3rd quarter 2024 earnings of 0.38 per share.
The next earnings announcement is expected on Dec 10, 2024.
Average growth rate-16.54%
Carl Zeiss Meditec AG reported annual 2023 earnings of 3.25 per share on Dec 12, 2023.
Average growth rate+23.16%
More ▼

Revenue history & estimates in EUR

Carl Zeiss Meditec AG had 3rd quarter 2024 revenues of 539.30m. This bettered the 533.32m consensus of the 7 analysts covering the company. This was 14.67% above the prior year's 3rd quarter results.
Average growth rate+0.97%
Carl Zeiss Meditec AG had revenues for the full year 2023 of 2.09bn. This was 9.80% above the prior year's results.
Average growth rate+10.04%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.